Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 tivantinib versus placebo in MET-high inoperable hepatocellular carcinoma after prior sorafenib
NL-OMON41234Phase 3Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing tivantinib with placebo (2 arms). Primary endpoint: overall survival. Started Nov 2013; status: active, not recruiting.
02
Drugs
tivantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NL-OMON41234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41234.